Creso Pharma Ltd (ASX: CPH)

Launched first animal health product in Switzerland: Creso Pharma Ltd (ASX: CPH), the Australian-Swiss company, along with Virbac (global pharmaceutical animal health company) has launched anibidiol®, in Switzerland. This is a natural complementary feed and first Swiss approved hemp product for companion animals containing a standardized amount of hemp extract with cannabidiol (CBD), the non-psychoactive substance of the hemp plant. The group is otherwise also tracking well with the development of hemp-based nutraceuticals for humans and animals. Recently, the group hailed Canada’s new proposed tax regime for recreational cannabis given the purchase of Mernova Medical in the region. Meanwhile, the shares of CPH surged over 239.1% this year to date (as of November 13, 2017) and were up 2.5% on November 14, 2017, placing the stock at slightly high levels. We give a “Hold” recommendation on the stock at the current price of $0.80
 

anibidiol® Products (Source: Company Reports)
 

AusCann Group Holdings Ltd (ASX: AC8)

Progressing well on plans: AusCann (ASX: AC8) share has risen 95% in last one month and 34% in last five days, as at November 13, 2017. However, the stock plunged 7.5% on November 14, 2017 which may be owing to some profit-booking activity. AusCann has been positioned as the only company in the region with fully integrated capability to grow and manufacture cannabis medicines in Australia. The growth prospects look favourable with progress of operations in Australia with key licences granted, medical Liaison Managers been appointed to lead Medical Outreach program across Australia and evolving regulatory advances. The passing of the Medicinal Cannabis Legislation Amendment (Securing Patient Access) Bill 2017 is of particular significance.

In addition to progress in Australia, the group’s strategic partner Tasmanian Alkaloids was granted a research and development licence, and a cultivation licence for its Tasmania site. Going forward, AC8 aims to have the Tasmanian site ready for planting in 2018, and accordingly, has got its cultivation and manufacturing team to work with Tasmanian Alkaloids in preparing the cultivation and manufacturing facilities. We give a “Buy” on the stock at the current price of $0.74

Disclaimer
 
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.